Literature DB >> 21956756

Detection of deleted in malignant brain tumors 1 and runt-related transcription factor 3 gene expressions in bladder carcinoma.

Yavuz Dodurga1, Cığır Biray Avcı, N Lale Satiroglu-Tufan, Canten Tataroglu, Zehra Kesen, Z Ozlem Doğan, Sunde Yılmaz, Cumhur Gündüz.   

Abstract

Bladder cancer is the fifth most commonly diagnosed cancer in the United States, where the majority of tumors are transitional cell carcinoma. Deleted in malignant brain tumors 1 (DMBT1) gene is located at chromosome 10q25.3-q26.1. DMBT1 gene expression has yet to be investigated in patients with bladder cancer. Runt-related transcription factor 3 (RUNX3) is a candidate tumor suppressor gene which is localized on the chromosome 1p36. RUNX3 gene expression in bladder carcinogenesis is particularly unknown. We aimed to evaluate DMBT1 and RUNX3 gene expression profiles in bladder cancer and how their expressions could be related to carcinogenesis in the bladder and their correlation with clinicopathological parameters. Fifty-six paraffin embedded specimens of transitional cell carcinoma of the urinary bladder were used. Total RNA was extracted from bladder specimens and cDNA was synthesized. The quantification of DMBT1 and RUNX3 mRNAs were succeeded according to the manufacturers' instructions by using RT-PCR. DMBT1 and RUNX3 gene expressions were identified in 100% of bladder carcinoma samples. No significant association was found in these genes expression levels when compared to sex and age. RUNX3 gene expression was decreased non-significantly in high-grade tumors. When DMBT1 gene expression was compared to tumor grades, a significant decrease was detected between grade I and III (P = 0.028). Disruption of expression in relation to tumor suppressors like DMBT1 and RUNX3 genes was associated with bladder cancer. Furthermore, detailed studies including these genes should be performed in protein levels and used more patient specimens in a large scale study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956756     DOI: 10.1007/s11033-011-1261-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  23 in total

1.  Asymmetric distribution of oncogene products at mitosis.

Authors:  B Czerniak; F Herz; R P Wersto; L G Koss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis.

Authors:  Kunio Araki; Mitsuhiko Osaki; Yumi Nagahama; Toshiki Hiramatsu; Hiroshige Nakamura; Shigetsugu Ohgi; Hisao Ito
Journal:  Cancer Sci       Date:  2005-04       Impact factor: 6.716

3.  The RUNX3 gene--sequence, structure and regulated expression.

Authors:  C Bangsow; N Rubins; G Glusman; Y Bernstein; V Negreanu; D Goldenberg; J Lotem; E Ben-Asher; D Lancet; D Levanon; Y Groner
Journal:  Gene       Date:  2001-11-28       Impact factor: 3.688

4.  DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours.

Authors:  J Mollenhauer; S Wiemann; W Scheurlen; B Korn; Y Hayashi; K K Wilgenbus; A von Deimling; A Poustka
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

5.  RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

Authors:  Wun-Jae Kim; Eun-Jung Kim; Pildu Jeong; Changyi Quan; Jiyeon Kim; Qing-Lin Li; Jeong-Ook Yang; Yoshiaki Ito; Suk-Chul Bae
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

6.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer.

Authors:  G S Bova; B S Carter; M J Bussemakers; M Emi; Y Fujiwara; N Kyprianou; S C Jacobs; J C Robinson; J I Epstein; P C Walsh
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

7.  Carcinogen inducibility in vivo and down-regulation of DMBT1 during breast carcinogenesis.

Authors:  Jan Mollenhauer; Burkhard Helmke; Daniel Medina; Gaby Bergmann; Nikolaus Gassler; Hanna Müller; Stefan Lyer; Laura Diedrichs; Marcus Renner; Rainer Wittig; Stephanie Blaich; Ute Hamann; Jens Madsen; Uffe Holmskov; Floris Bikker; Antoon Ligtenberg; Anette Carlén; Jan Olsson; Herwart F Otto; Bert O'Malley; Annemarie Poustka
Journal:  Genes Chromosomes Cancer       Date:  2004-03       Impact factor: 5.006

Review 8.  Salivary agglutinin/glycoprotein-340/DMBT1: a single molecule with variable composition and with different functions in infection, inflammation and cancer.

Authors:  Antoon J M Ligtenberg; Enno C I Veerman; Arie V Nieuw Amerongen; Jan Mollenhauer
Journal:  Biol Chem       Date:  2007-12       Impact factor: 3.915

9.  Loss of the chromosomal region 10q23-25 in prostate cancer.

Authors:  I C Gray; S M Phillips; S J Lee; J P Neoptolemos; J Weissenbach; N K Spurr
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

10.  Rare mutations of the DMBT1 gene in human astrocytic gliomas.

Authors:  Wolf Mueller; Jan Mollenhauer; Florian Stockhammer; Annemarie Poustka; Andreas von Deimling
Journal:  Oncogene       Date:  2002-08-29       Impact factor: 9.867

View more
  1 in total

1.  An electrochemiluminescence assay for gp340 (DMBT1).

Authors:  Cheryl Barber; Drew Weissman; Kurt Barnhart; Minal Dalvi; William R Abrams; Daniel Malamud
Journal:  Anal Biochem       Date:  2013-05-30       Impact factor: 3.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.